CA-4	Combretastatin A-4
DBU	1,8-Diazabicyclo[5.4.0]undec-7-ene
DCC	N,N′-Dicyclohexyl carbodiimide
DCM	Dichloromethane
DCTD	Division of Cancer Treatment and Diagnosis
DEAD	Diethyl azodicarboxylate
DIPEA	N,N-diisopropylethylamine
DMAP	4-Dimethylaminopyridine
DMF	N,N-Dimethylformamide
DTP	Development Therapeutics Program
Et3N	Triethylamine
EBI	N,N′-Ethylene-bis(iodoacetamide)
ESI	Electrospray ionisation
FMOC	Fluorenylmethyloxycarbonyl
HPLC	High-performance liquid chromatography
HRMS	High Resolution Mass Spectrometry
IC	Inhibitory concentration
IR	Infrared
MIC	Minimum inhibitory concentration
MTD	Maximum tolerated dose
MS	Mass spectrometry
NCI	National Cancer Institute
NIH	National Institute of Health
NMR	Nuclear Magnetic Resonance
PBS	Phosphate-buffered saline
SAR	Structure-activity relationship
SERM	Selective Estrogen Receptor Modulator
TBAF	Tetrabutylammonium fluoride
TBDMS	tert-Butyldimethylchlorosilane
TEA	Triethylamine
TLC	Thin layer chromatography
TMS	Tetramethylsilane
TMCS	Tetramethylchlorosilane
UV	Ultraviolet
VDA	Vascular disrupting agent